Related Experiment Video
Updated: May 27, 2026
09:04
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Nematode modulation of inflammatory bowel disease
Rose A K Whelan1, Susanne Hartmann, Sebastian Rausch
1Department of Molecular Parasitology, Humboldt University of Berlin, 10115, Berlin, Germany.
Protoplasma
|November 17, 2011
Summary
Helminth infections, common in developing nations, may protect against inflammatory bowel disease (IBD). These parasitic worms can suppress the immune system, offering potential new treatments for IBD.
Area of Science:
- Gastroenterology
- Immunology
- Parasitology
Background:
- Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder linked to genetic, environmental, and lifestyle factors.
- Lower IBD prevalence in developing nations correlates with higher helminth infection rates.
- Gastrointestinal nematodes are parasites that modulate host immune responses.
Purpose of the Study:
- To review how nematodes and their products suppress inflammatory immune responses.
- To explore the mechanisms by which anti-nematode responses regulate colitis.
- To discuss the potential of nematode-derived therapies for IBD and other inflammatory disorders.
Main Methods:
- Review of existing literature on helminth infections and inflammatory bowel disease.
- Analysis of immune modulation mechanisms by nematodes.
- Examination of experimental models and clinical trials involving nematode therapies for colitis.
Main Results:
- Nematodes and their products effectively suppress innate and adaptive pro-inflammatory immune responses.
- Mechanisms involved in anti-nematode immunity can regulate experimental colitis.
- Nematode-derived therapies show promise in preclinical and clinical settings for IBD.
Conclusions:
- Helminth infections may offer a protective effect against IBD.
- Understanding nematode-induced immune suppression can lead to novel therapeutic strategies.
- Refined nematode-derived therapies hold potential for treating clinical inflammatory disorders.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...